# ClinicalTrials.gov record NCT02716974

> PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02716974-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-08-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02716974-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02716974-leuprolide-v1.json
- Content SHA-256: `5149a6e73ff677e09d3bd53825f8f681552784a055c7f572ec80098bef5c046f`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02716974 ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02716974 at 2026-07-30T19:36:31.405Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`](#source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e))

## Sources

<a id="source-ctg-observation-nct02716974-2022-08-04-ef6443d8759e"></a>
- **ClinicalTrials.gov record NCT02716974 · retained source version 2022-08-04:ef6443d8759ead77a6f000503cf1d88249785020fb1fc28885b469b92f47aaa7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02716974) (`ctg-observation-nct02716974-2022-08-04-ef6443d8759e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02716974." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02716974-leuprolide-v1.json SHA-256: 5149a6e73ff677e09d3bd53825f8f681552784a055c7f572ec80098bef5c046f.